Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire-based, cross-sectional study.

Tanifuji, Ayaka; Ohfuji, Satoko; Matsumoto, Kosuke; Abe, Masanori; Komori, Atsumasa; Takahashi, Atsushi; Kawata, Kazuhito; Sato, Ken; Joshita, Satoru; Umemura, Takeji; Ueno, Masayuki; Nakayama, Nobuaki; Kakisaka, Keisuke; Arinaga-Hino, Teruko; Ito, Koichi; Kanai, Sachiko; Miura, Ryo; Arizumi, Toshihiko; Asaoka, Yoshinari; Ito, Takanori; Shimizu, Tetsuya; Yoshida, Hiroshi; Ohta, Masayuki; Mizuno, Suguru; Isayama, Hiroyuki; Morimoto, Youichi; Mochida, Satoshi; Ohira, Hiromasa; Tanaka, Atsushi

Tanifuji, Ayaka; Ohfuji, Satoko; Matsumoto, Kosuke; Abe, Masanori; Komori, Atsumasa; Takahashi, Atsushi; Kawata, Kazuhito; Sato, Ken; Joshita, Satoru; Umemura, Takeji; Ueno, Masayuki; Nakayama, Nobuaki; Kakisaka, Keisuke; Arinaga-Hino, Teruko; Ito, Koichi; Kanai, Sachiko; Miura, Ryo; Arizumi, Toshihiko; Asaoka, Yoshinari; Ito, Takanori; Shimizu, Tetsuya; Yoshida, Hiroshi; Ohta, Masayuki; Mizuno, Suguru; Isayama, Hiroyuki; Morimoto, Youichi; Mochida, Satoshi; Ohira, Hiromasa; Tanaka, Atsushi.

Afiliação

Tanifuji A; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Ohfuji S; Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Matsumoto K; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Abe M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Komori A; Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki, Japan.
Takahashi A; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan.
Sato K; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan.
Joshita S; Division of Hepatology and Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.
Umemura T; Division of Hepatology and Gastroenterology, Department of Medicine, Shinshu University School of Medicine, Nagano, Japan.
Ueno M; Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama, Japan.
Nakayama N; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kakisaka K; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Arinaga-Hino T; Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Ito K; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Kanai S; Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Miura R; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Arizumi T; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Asaoka Y; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Ito T; Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Shimizu T; Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Yoshida H; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Ohta M; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan.
Mizuno S; Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Oita, Japan.
Isayama H; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Morimoto Y; Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Mochida S; Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama, Japan.
Ohira H; Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Tanaka A; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Hepatol Res ; 54(7): 706-715, 2024 Jul.

Article em En | MEDLINE | ID: mdl-38300669

ABSTRACT

ABSTRACT

AIM:

There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire-based, cross-sectional study to determine the safety and effectiveness of the SARS-CoV-2 vaccines in Japanese patients with intractable hepatobiliary disease.

METHODS:

Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post-vaccination adverse effects, and SARS-CoV-2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre- and post-vaccination were collected.

RESULTS:

The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH- primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd-Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post-vaccination adverse effects were comparable to those observed in the general population. Post-vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH-like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS-CoV-2, and only one patient was infected 6 months after the second vaccination.